Germany's Carl Zeiss Meditec reports drop in full-year profit

German medical technology company Carl Zeiss Meditec reported a drop in full-year profit to €142.3 million ($166 million), or €1.61 per share, down from €180.2 million, or €2.01 per share, last year.

The company's revenue for the period rose 7.8% to €2.23 billion from €2.07 billion last year.

Carl Zeiss Meditec said it has proposed a dividend of €0.55 per share for the year, less than €0.60 per share in the previous year.

Looking ahead, for fiscal 2025-26, the company expects revenue of €2.3 billion.

Earnings before interest and tax (EBIT) and before interest, taxes, depreciation and amortization (EBITA) are anticipated to continue their upward trend, helped by an improved product mix driven by increasing recurring revenue, particularly from the refractive laser business and the DORC portfolio within ophthalmology, as well as from growth in microsurgery.

The company expects its EBIT margin to be around 11% to 11.5%, while the EBITA margin is expected to reach around 12.5%.

For fiscal 2024-25, the company has posted an EBIT of €223.3 million, with an EBIT margin of 10%, and an EBITA of €257.7 million, with an EBITA margin of 11.6%.